How to Prevent a Global Aging Crisis
July 17, 2010 by David Despain
A handful of forward-thinking biogerontologists has joined together to offer a new direction for aging intervention. Their commentary, published July 14 in Science Translational Medicine, presents the case for preventing what the scientists call an “unprecedented global aging crisis”—a sharp rise in the numbers of retired elderly in developing and industrialized nations across the world.
From both a humane and economic standpoint, a world with too many sick elderly has grim consequences and outrageous costs. It’s time to fund research for prevention, slowing, or even reversal of the biological damage caused by simply living, which manifests as age-related diseases such as Alzheimer’s, cardiovascular disease, and cancer.
Currently, senescence research receives only a slim morsel of the researching-funding pie. Of the entire National Institutes of Health $28 billion budget, only about 0.1 percent (about $10 million) has been allocated for biological aging research, the scientists write. Of that $10 million morsel, only crumbs will make it to actual clinical studies on late-life aging interventions—despite the large economic and social implications of an increasing ratio of older to younger people.
Aging manifests itself as “a progressive, roughly synchronous rise in the incidence of disease, disability, and death from chronic diseases, beginning after midlife [examples in "Chronic diseases and aging" chart] and suggests a causal—rather than a casual—relationship,” the authors write.
Research Roadmap for Optimizing and Postponing Aging
A co-author of the paper, Aubrey de Grey, a biomedical gerontologist and author of the popular science book Ending Aging, sums up the case for a new way forward: “We argue for a more balanced approach to the quest for interventions to postpone age-related ill health.” De Grey, the Chief Science Officer of the SENS (Strategies for Engineering Negligible Senescence) Foundation (SENSF), Sunnyvale, California, is no stranger to the problems of finding funding for research, which is why he and his co-authors decided to write the commentary.
“There are no surprises there,” he says. “It’s all about the fact that biology is irreducibly expensive. In particular, as more and more of our research programs move from the cell culture stage into live mice, the expense rises sharply.”
The high cost of anti-aging research, de Grey says, is the greatest roadblock in the scientists’ roadmap, which consists of three intervention strategies pursued by researchers at SENSF and other organizations, including the International Longevity Center in New York, and the Andrus Gerontology Center, University of Southern California of Los Angeles):
- Reduce exposure to environmental toxins and ameliorate other risk factors through improved public health.
- Slow down damage to metabolic pathways, which contributes to age-related changes.
- Develop a more broadly conceived regenerative medicine to embrace the repair, removal, or replacement of existing aging damage or its decoupling from its pathological sequelae.
The authors highlight a 2006 article in The Scientist, co-authored by the former biomedical gerontologist Robert N. Butler of the International Longevity Center in New York: “The relative potential of these interventions and their combination is portrayed in [the "Postponing degeneration" chart], presented in terms of their ability to deliver a 7-year postponement of age-related degeneration.”
Unfortunately, most biogerontologists see aging-intervention strategies as a considerable deviance from mainstream thinking, which is based on the notion that aging is a certainty and that pursuit of any kind of “fountain of youth” or life-extension therapies will only end in failure.
But de Grey is not swayed by the skeptics. He says perspectives are changing: “Five of the other authors [of the paper] are among the absolute top tier of biogerontologists, whose views are universally respected in the field. Their voice here will make a huge impact on thinking about the issue, both within the field and beyond. ”
“The surprising conclusion from the past two decades of research on biological aging is that aging is plastic,” the authors of the paper state. “Within a species, maximum life span is not fixed, but can be increased by dietary manipulation (particularly calorie restriction) or genetic manipulation.”
But a new world of indefinite lifespans has also raised questions about potential population impacts. “Contrary to what is widely assumed, however, the net effect should be relatively minor,” the authors respond, reasoning that new human births have a greater effect on population than adding a fraction of life span to existing humans. “A policy of aging as usual will lead to enormous humanitarian, social, and financial costs. Efforts to avert that scenario are unequivocally merited, even if those efforts are costly and their success and full consequences uncertain. To realize any chance of success, the drive to tackle biological aging head-on must begin now.”
These new perspectives about the importance of biological aging research and how it should be carried out are welcome news for scientists researching pre-disease interventions and human regenerative-engineering therapies, and for those of us who would one day like the chance to share moments with our great-great-great-great grandchildren.
The demographic and biomedical case for late-life interventions in aging. Sci. Transl. Med. 2, 40cm21 (2010). Supplementary Material (free full-text access)
In pursuit of the longevity dividend.The Scientist, 20: 28-36.
SENSF Solutions to Seven Causes of Aging Damage
Over the past decade, Aubrey de Grey has identified seven “major categories of molecular and cellular ‘damage’ that I believe we need to repair (or in some cases obviate) to rejuvenate the aged body comprehensively, and ways to implement that repair”:
- Cell loss, tissue atrophy
- Nuclear mutations
- Mutant mitochondria
- Death-resistant cells
- Tissue stiffening
- Extracellular aggregates
- Intracellular aggregates
These interventions include repairing the body with stem cell therapies to combat cell loss, “suicide” gene therapy to act against death-resistant cells, and enzymes or vaccinations for cleaning out intracellular and extracellular “molecular garbage. ”
SENSF also directs research on small-molecule drugs that can act against spontaneous cross-links in the extracellular matrix, nuclear copies of the mitochondrial DNA to avert mitochondrial mutations, and complex combination therapy to suppress telomere elongation (telomeres are a repetitive DNA sequence protecting the end of chromosomes from degeneration, like the plastic tips on shoelaces), using a variety of stem-cell therapies to preempt cancer.
De Grey says the foundation’s priorities are long-term research commitments. In the coming few years, ”I believe the main benefits we can expect to see will come from public health advances, and possibly from drugs to optimize metabolism. These will act as a ‘bridge’ to allow more people to survive in a healthy state.”